CRISPR precision,
now in clinical diagnostics
The scopeDx® detection technology behind our on-site crop tests is now part of a CE marked clinical test under the EU IVDR. This makes it the first CRISPR-Cas diagnostic with a CE mark.
We work with diagnostics manufacturers to bring fast, simple, single-nucleotide precision to their products.
Regulatory Status
CE marked, IVDR
Time to Result
45 Minutes
Resolution
Single Nucleotide
Partner
Amplex Diagnostics
FIRST CLINICAL APPLICATION
eazySNP C. auris
FKS1 S639
Developed with AmplexDiagnostics GmbH, eazySNP detects mutations in Candida auris that are associated with resistance to echinocandins, the recommended initial treatment for most C. auris infections.
C. auris is a yeast that can cause severe and life-threatening infections. When a strain carries a resistance mutation, echinocandins are ineffective, while alternative antifungal treatment still works. eazySNP runs from a yeast colony on Amplex's eazyMini instrument and delivers a result in approximately 45 minutes.
For product information, availability and ordering, please contact AmplexDiagnostics. [LINK TO AMPLEX PRODUCT PAGE]
THE TECHNOLOGY
One platform, from field to clinic.
scopeDx® combines isothermal DNA amplification with our proprietary CRISPR type III detection. The result is a molecular test that tells apart genetic sequences differing by a single nucleotide, without the complexity of a central lab workflow.
Amplify
Isothermal amplification copies the target DNA at a single temperature, so no thermal cycler is needed.
Detect
Our CRISPR type III system recognises the target sequence with single-nucleotide precision, distinguishing a resistance mutation from the wild type.
Integrate
The chemistry is built into a partner's product and runs on existing diagnostic instruments, as eazySNP does on the eazyMini.
HOW WE WORK
We build with partners who know the clinic.
In agriculture we take our tests to market ourselves. In human diagnostics we work with established manufacturers, combining our detection technology with their clinical expertise, regulatory experience and distribution.
We are looking for partners on tests where simplicity, speed and molecular precision matter.
Assay co-development
Joint development of a new test on your instrument, from target selection to a product ready for regulatory submission.
Feasibility Studies
A focused project to test whether your target, mutation or marker is a good fit for our platform.
Technology Licensing
Access to our CRISPR type III detection for integration into your own diagnostic portfolio.
Research Collaborations
Work with clinical and academic groups on new applications, validation studies and grant consortia.
“For Scope, eazySNP is an important step: our proprietary CRISPR type III technology is now part of a CE marked clinical test. Working with Amplex shows how we can bring our detection technology into products with an established diagnostics manufacturer.’’
— Bas van der Baan, CEO, Scope Biosciences B.V.
PROVEN IN THE FIELD
The same platform already runs on-site crop pathogen tests.
A Wageningen University & Research spin-out, Scope Biosciences develops scopeDx® tests used by seed producers including Syngenta, KWS and Bejo.
GET IN TOUCH
Let’s build the next test
together
Diagnostics manufacturer, clinical lab, research group or investor: tell us what you are working on and the right person on our team will get back to you within two working days.